As of 2026-09-15, the EV/EBITDA ratio of Regenxbio Inc (RGNX) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RGNX's latest enterprise value is 695.01 mil USD. RGNX's TTM EBITDA according to its financial statements is -148.78 mil USD. Dividing these 2 quantities gives us the above RGNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.6x - 17.8x | 17.2x |
| Forward P/E multiples | 20.1x - 23.7x | 20.7x |
| Fair Price | (49.45) - (44.04) | (46.84) |
| Upside | -669.0% - -606.8% | -639.0% |
| Date | EV/EBITDA |
| 2026-09-04 | -4.78 |
| 2026-09-03 | -4.89 |
| 2026-09-02 | -5.06 |
| 2026-09-01 | -4.94 |
| 2026-08-31 | -5.02 |
| 2026-08-28 | -5.08 |
| 2026-08-27 | -4.96 |
| 2026-08-26 | -4.97 |
| 2026-08-25 | -4.77 |
| 2026-08-24 | -4.40 |
| 2026-08-21 | -5.54 |
| 2026-08-20 | -5.68 |
| 2026-08-19 | -6.09 |
| 2026-08-18 | -5.68 |
| 2026-08-17 | -5.79 |
| 2026-08-14 | -5.55 |
| 2026-08-13 | -5.51 |
| 2026-08-12 | -5.62 |
| 2026-08-11 | -5.51 |
| 2026-08-10 | -5.41 |
| 2026-08-07 | -5.54 |
| 2026-08-06 | -5.77 |
| 2026-08-05 | -5.44 |
| 2026-08-04 | -5.36 |
| 2026-08-03 | -5.21 |
| 2026-07-31 | -5.10 |
| 2026-07-30 | -5.28 |
| 2026-07-29 | -5.07 |
| 2026-07-28 | -5.06 |
| 2026-07-27 | -5.11 |
| 2026-07-24 | -5.11 |
| 2026-07-23 | -5.34 |
| 2026-07-22 | -5.31 |
| 2026-07-21 | -5.37 |
| 2026-07-20 | -5.36 |
| 2026-07-17 | -5.18 |
| 2026-07-16 | -5.74 |
| 2026-07-15 | -6.19 |
| 2026-07-14 | -6.20 |
| 2026-07-13 | -6.40 |
| 2026-07-10 | -6.91 |
| 2026-07-09 | -7.63 |
| 2026-07-08 | -7.45 |
| 2026-07-07 | -7.36 |
| 2026-07-06 | -7.28 |
| 2026-07-02 | -6.62 |
| 2026-07-01 | -6.54 |
| 2026-06-30 | -6.07 |
| 2026-06-29 | -6.01 |
| 2026-06-26 | -5.43 |